Dublin-based Allergan has undergone many changes recently, with the acquisition by Actavis, the failed merger with Pfizer, and the divestiture of the generics business to Teva. The company’s SVP and President of Asia Pacific, Rajkumar Narayanan, speaks about the bold new Allergan that has emerged following these events and details their plans to capitalize on the potential in medical aesthetics, with China and Japan at the forefront.
It’s been a rather eventful time for Allergan these past two years since you started this role. After all the dust has settled, where does Asia Pacific stand in terms of strategic importance?
We’ve branded ourselves as growth pharma, and clearly Asia Pacific is one of the regions driving that growth
